954 Clinical results from a phase I dose escalation study in treatment-naïve early stage prostate cancer patients with ORCA-010, a potency enhanced oncolytic replication competent adenovirus

Bibliographic Details
Published in:Journal for ImmunoTherapy of Cancer
Main Authors: Richard Casey, Wenliang Dong, Tereza Brachtlova, Allan Abramovitch, Jonathan Giddens, Peter Incze, Kenneth Jansz, Victor van Beusechem
Format: Article in Journal/Newspaper
Language:English
Published: BMJ Publishing Group 2021
Subjects:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Orca
Online Access:https://doi.org/10.1136/jitc-2021-SITC2021.954
https://doaj.org/article/2c4cd2b93c724d0e9682c4265c27a61a
id ftdoajarticles:oai:doaj.org/article:2c4cd2b93c724d0e9682c4265c27a61a
record_format openpolar
spelling ftdoajarticles:oai:doaj.org/article:2c4cd2b93c724d0e9682c4265c27a61a 2023-05-15T17:53:22+02:00 954 Clinical results from a phase I dose escalation study in treatment-naïve early stage prostate cancer patients with ORCA-010, a potency enhanced oncolytic replication competent adenovirus Richard Casey Wenliang Dong Tereza Brachtlova Allan Abramovitch Jonathan Giddens Peter Incze Kenneth Jansz Victor van Beusechem 2021-11-01T00:00:00Z https://doi.org/10.1136/jitc-2021-SITC2021.954 https://doaj.org/article/2c4cd2b93c724d0e9682c4265c27a61a EN eng BMJ Publishing Group https://doaj.org/toc/2051-1426 doi:10.1136/jitc-2021-SITC2021.954 2051-1426 https://doaj.org/article/2c4cd2b93c724d0e9682c4265c27a61a Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021) Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 article 2021 ftdoajarticles https://doi.org/10.1136/jitc-2021-SITC2021.954 2022-12-31T15:37:04Z Article in Journal/Newspaper Orca Directory of Open Access Journals: DOAJ Articles Journal for ImmunoTherapy of Cancer 9 Suppl 2 A1004 A1004
institution Open Polar
collection Directory of Open Access Journals: DOAJ Articles
op_collection_id ftdoajarticles
language English
topic Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Richard Casey
Wenliang Dong
Tereza Brachtlova
Allan Abramovitch
Jonathan Giddens
Peter Incze
Kenneth Jansz
Victor van Beusechem
954 Clinical results from a phase I dose escalation study in treatment-naïve early stage prostate cancer patients with ORCA-010, a potency enhanced oncolytic replication competent adenovirus
topic_facet Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
format Article in Journal/Newspaper
author Richard Casey
Wenliang Dong
Tereza Brachtlova
Allan Abramovitch
Jonathan Giddens
Peter Incze
Kenneth Jansz
Victor van Beusechem
author_facet Richard Casey
Wenliang Dong
Tereza Brachtlova
Allan Abramovitch
Jonathan Giddens
Peter Incze
Kenneth Jansz
Victor van Beusechem
author_sort Richard Casey
title 954 Clinical results from a phase I dose escalation study in treatment-naïve early stage prostate cancer patients with ORCA-010, a potency enhanced oncolytic replication competent adenovirus
title_short 954 Clinical results from a phase I dose escalation study in treatment-naïve early stage prostate cancer patients with ORCA-010, a potency enhanced oncolytic replication competent adenovirus
title_full 954 Clinical results from a phase I dose escalation study in treatment-naïve early stage prostate cancer patients with ORCA-010, a potency enhanced oncolytic replication competent adenovirus
title_fullStr 954 Clinical results from a phase I dose escalation study in treatment-naïve early stage prostate cancer patients with ORCA-010, a potency enhanced oncolytic replication competent adenovirus
title_full_unstemmed 954 Clinical results from a phase I dose escalation study in treatment-naïve early stage prostate cancer patients with ORCA-010, a potency enhanced oncolytic replication competent adenovirus
title_sort 954 clinical results from a phase i dose escalation study in treatment-naïve early stage prostate cancer patients with orca-010, a potency enhanced oncolytic replication competent adenovirus
publisher BMJ Publishing Group
publishDate 2021
url https://doi.org/10.1136/jitc-2021-SITC2021.954
https://doaj.org/article/2c4cd2b93c724d0e9682c4265c27a61a
genre Orca
genre_facet Orca
op_source Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
op_relation https://doaj.org/toc/2051-1426
doi:10.1136/jitc-2021-SITC2021.954
2051-1426
https://doaj.org/article/2c4cd2b93c724d0e9682c4265c27a61a
op_doi https://doi.org/10.1136/jitc-2021-SITC2021.954
container_title Journal for ImmunoTherapy of Cancer
container_volume 9
container_issue Suppl 2
container_start_page A1004
op_container_end_page A1004
_version_ 1766161075712032768

Similar Items